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Abstract
Migraine is considered mostly a woman’s complaint, even if it affects also men. Epidemiological data show a higher incidence of
the disease in women, starting from puberty throughout life. The sex-related differences of migraine hold clinical relevance too.
The frequency, duration, and disability of attacks tend to be higher in women. Because of this, probably, they also consult
specialists more frequently and take more prescription drugs than men. Different mechanisms have been evaluated to explain
these differences. Hormonal milieu and its modulation of neuronal and vascular reactivity is probably one of the most important
aspects. Estrogens and progesterone regulate a host of biological functions through two mechanisms: nongenomic and genomic.
They influence several neuromediators and neurotransmitters, and they may cause functional and structural differences in several
brain regions, involved in migraine pathogenesis. In addition to their central action, sex hormones exert rapid modulation of
vascular tone. The resulting specific sex phenotype should be considered during clinical management and experimental studies.
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Introduction
Migraine is generally considered a woman’s complaint owing to
its preponderance among women and the greater healthcare re-
source use by women for migraine headache. Epidemiological
data subdivide the prevalence of migraine by age group. In pre-
pubertal children, the 1-year prevalence is roughly the same for
boys and girls (overall range, 2–5%; 2.4% and 2.5% in girls and
boys, respectively, aged 7–9 years; 5.4% and 3.9% in girls and
boys, respectively, aged 10–12 years) [1]. Starting at puberty
with its accompanying hormonal changes, the prevalence in-
creases in both sexes, and it is higher in girls than boys from
13 to 15 years (6.4% and 4.0%, respectively). This sex-related
difference in prevalence remains throughout life. Between 10
and 20%ofwomen report experiencing their first migraine attack
at the start of menarche [2]. Migraine incidence peaks first at
around age 35 years (25–30% of women and 8% of men) [3]
and then again at around age 50, after which it declines with
advancing age [4]. The elderly suffer less frequently from mi-
graine but more often from secondary headache than young
people. The decline in migraine frequency is proportional to
advancing age, starting at the sixth/seventh decade, and further
decreases after age 75. Nevertheless, new onset migraine after
age 65 is noted to occur in 0.5% of the population [5].
The American Migraine Prevalence and Prevention
(AMPP) study reported a cumulative incidence of lifetime
migraine in 43% of women and 18% of men [6], a slightly
lower rate than more recent data reveal, according to which
the risk of migraine is 3.25 times higher for women than for
men [4, 7]. The estimated prevalence of migraine in the Italian
population is 32.9% in women and 13.0% inmen [4]. A recent
national survey of pharmacies in Italy revealed a prevalence of
43% of “definite migraine” (defined by the IDMigraine ques-
tionnaire) [7] in a female-to-male ratio of 4.9: 1 [8]. These
survey findings show that migraine is much more common
in the general population than the data from public healthcare
databases would indicate; the reason is that many migraine
sufferers choose to self-medicate rather than consult a head-
ache specialist for diagnosis and treatment.
Clinical characteristics of migraine in men
and women
The sex-related differences of migraine hold epidemiological
and clinical relevance. Most studies agree that there are no
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sex-related differences in attack frequency: 1 to 4 monthly
headache days (MHD) on average for both sexes (48.8% in
women and 45.3% in men) [4, 9, 10]. Bolay reported that high
frequency migraine (> 10 MHD) is more common among
men than women (16.7% and 14.9%, respectively; prevalence
rate [PR] 0.90; 95% confidence interval [CI] 0.83–0.97).
Attack frequency differs between age groups: migraine with-
out aura (MO) is higher among 18–29-year-olds than among
40–49-year-olds (p < 0.0001) and after age 50 (p = 0.0013).
Similarly, migraine with aura (MA) is more frequent in wom-
en aged 18 to 29 years than in those aged 30 to 39 years (p =
0.0308). This difference in attack frequency between age
groups is significant for women but not for men migraineurs
[10]. Attack duration of MO and MA is also age-related:
shorter in 18–29-year-olds and longer in women aged 30
and over (p = 0.0407 for MO and p = 0.0043 for MA).
Most studies report longer attack duration in women than in
men (28.4 h in men and 36.7 h in women; p = 0.01) and a higher
recurrence rate. Study findings diverge on whether attack inten-
sity differs between the sexes [4, 10–13]. Because the perception
of pain intensity is subjective, whereas attack duration is an ob-
jectivemeasure, some researchers report that, at equal pain scores
for men and women, the longer duration of attacks and recovery
time may be the reasons why women grade their pain intensity
higher than men. Added to this is the commonplace belief that,
because of gender roles, men are less likely to rate their percep-
tion of pain intensity as high [14].
In general, the characteristic symptoms accompanying mi-
graine (e.g., nausea, vomiting, phonophobia, photophobia, cu-
taneous allodynia) are more frequent among women than men
[4, 10–13]. Studies have found that, except for vomiting,
among patients with MO, nausea, phonophobia, and photo-
phobia are significantly more frequent in women (p < 0.001
for all symptoms), whereas among patients with MA, sex-
related differences were found for nausea (65.6% in women
and 48.6% in men; p = 0.049) and phonophobia (70.2% in
women and 51.4% in men; p = 0.033) but not for vomiting
and photophobia [9].
MA is less frequent than MO in both men and women. A
UK study [15] reported a MA 1-year prevalence of 5.8%
(2.6% in men and 7.7% in women). MA is more prevalent
among women (range, 2.6–10.8% in women and 1.2–3.7% in
men) [16]. The frequency of symptoms accompanying aura
differs between the sexes: visual aura (1.8% in men and 4.2%
in women); sensorimotor aura (0.3% in men and 1.7% in
women); and visual and sensorimotor aura combined (0.4%
in men and 1.9% in women) [15].
The Global Burden of Disease study (2015) classified mi-
graine as the fourth leading cause of years living with disability
(YLD) for women and the eighth cause among men [17], indi-
cating that disability due tomigraine is another sex-related factor.
Women are 1.34 timesmore likely (95%CI 1.21–1.48) thanmen
(12.4% for women and 9.3% for men) to report grade IV
disability due to migraine in the past 3 months on the Migraine
Disability Assessment (MIDAS) questionnaire. Women are also
more likely to report inability to carry out household chores (odds
ratio [OR] 1.5, 95%CI 1.44–1.56), to take part in social or family
activities (OR 1.11, 95% CI 1.06–1.17), and to reduce by at least
50% work or school activity for at least 1 day due to migraine
[10]. Studies consistently report greater migraine-related disabil-
ity in women: 34% of women and 25% of men stated that they
lost work or school time more than rarely. Further, over 45% of
patients who reported having never or only rarelymissedwork or
school days due to migraine stated that they needed 2 h of bed
rest on average [12]. Whereas women reported that they were
unable to resume their daily activities for 3 to 6 days after an
attack, men stated that they resumed activities on the second day
after an attack [10].
The impact of migraine-related disability is especially crit-
ical for the toll it takes on the quality of life of migraine
sufferers besides the social costs it incurs. A US study pub-
lished in 1999 [18] reported that women generated about 80%
of medical costs directly correlated with migraine treatment
and that the indirect costs correlated with lost productivity
were 50% higher for women than for men. These data are
underestimated since they do not take into account unemploy-
ment and underemployment rates due to migraine. The esti-
mated annual mean pro capita cost of migraine is €1222 (95%
CI 1055–1389) in Europe, 93% ofwhich are indirect costs. No
data on sex-related differences in costs are available [19].
Overall, these sex-related differences in the clinical and epi-
demiological aspects of migraine translate into differences in
migraine treatment between men and women. An Italian survey
of patients who purchase headache pain relievers at a pharmacy
revealed that men consult a doctor less often than women for
treatment (65.7% and 72.4%, respectively; p = 0.003; OR 0.71,
95% CI 0.57–0.89), whereas women are more likely to talk with
their primary provider (40.5% and 35.9%, respectively; p =
0.082; OR 1.211 95% CI 0.976–1.503) or contact a headache
center (21.7% and 17.4%; p = 0.004, OR 1.31 95% CI 1–07-
1.72) [20]. Unlike men, women are more likely to visit the emer-
gency department because of intense migraine pain. These data
are consistent with the data for the percentage difference between
the sexes in medications use for acute migraine attack or prophy-
laxis. Compared with men, women use more prescription med-
ications (PR 1.33, 95% CI 1.23–1.43) and are more likely to use
triptans (OR 1.41, 95%CI 1.12–1.78) or drug combinations (OR
1.49, 95% CI 1.04–2.14) but less likely not to take acute medi-
cations (PR 0.65, 95%CI 0.52–0.80) [10, 11, 13]. In contrast, no
significant difference between the sexes was found for the use of
nonsteroidal anti-inflammatory drugs or ergot derivatives (55.6%
vs. 51.6% and 8.7% vs. 9.3%, respectively) [20]. Women are
more likely than men to use preventive treatment (OR 1.37, 95%
CI 1.27–1.48). While guidelines for the acute and preventive
management of migraine make no distinction between the sexes
(except for menstrual migraine treated with hormone therapy),
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sex differences in the pharmacokinetics of triptans are well doc-
umented: peak plasma concentration (Cmax) and area under the
curve (AUC) of plasma concentration are higher in women [21].
The clinical relevance of these sex-related differences in triptans
pharmacokinetics is controversial since studies have found no
correlation between these data and patient response. A study
comparing four different triptans found no significant difference
in treatment response or recurrence rates at 24 and 48 h between
men and women [22].
Data disagree on the likelihood that female sex is a risk
factor for transition from episodic to chronic migraine. Some
studies have reported that the transition in women is more
likely (OR 2.9 95% CI 1.2–6.9) [11], while others have found
a nearly similar transition rate within 1 year (5.4% in men and
4.4% in women) [23].
Compared with men with migraine, women migraineurs
have more comorbidities (average, 11 and 5 comorbidities in
women andmen, respectively) andmoremental comorbidities
(e.g., anxiety and depression), whereas men have more somat-
ic disorders (e.g., obesity). The data for these differences are
discrepant, however. Restless legs syndrome is associated
with migraine and is more common among women than
men in the general population; however, some studies have
reported a greater risk for developing the syndrome in men
migraineurs [24].
Migraine is a recognized risk factor for the development of
cardiovascular disease. Because most studies have involved
female subjects, the data for males are scarce. The risk of
ischemic stroke is twofold higher for women with MA. The
data for defining the risk of hemorrhagic stroke in men are
insufficient. The incidence of myocardial infarction seems to
be higher among migraineurs than nonmigraineurs (OR 1.33,
95% CI 1.08–1.64), but small male sample size precludes
reliable analysis of sex-related differences. MA is associated
with a higher risk of venous thrombosis in patients under age
55 years (adjusted hazard ratio [aHR] 3.322, 95% CI 1.509–
7.312), specifically among women (aHR 2.81, 95% CI 1.41–
5.58 for women and aHR 1.81, 95% CI 0.72–4.55 for men)
[11, 25].
Numerous factors underlie the sex-related differences in
migraine characteristics: hormonal, genetic, epigenetic, and
environmental aspects contribute in different ways to brain
structure, function, and plasticity.
Migraine pathophysiology in female
Sex hormones Estrogens and progesterone regulate a host of
biological functions through two mechanisms: nongenomic
and genomic [26, 27]. Owing to their lipophilic nature and
low molecular weight, sex hormones can cross the blood-
brain barrier, resulting in similar concentrations in systemic
and cerebral circulation [28]. The diverse enzymes involved in
sex hormone production are also found in the brain [29].
Three nongenomic mechanisms by which sex hormones
influence the central nervous system and its excitability are
distinguished: modulation of the interaction between receptors
and ligands; alteration of conductance of ion channels through
allosteric modulation; and increase in neuron excitability after
acute exposure [30].
The genomic mechanisms involved in the central action of
sex hormones are explicated through the activation of two
estrogen receptors (ERα and ERβ) and two progesterone re-
ceptors (PR-A and PR-B). They modulate the production and
metabolic pathways of various neurotransmitters and hor-
mones: calcitonin gene–related peptide (CGRP), serotonin,
glutamate, noradrenalin, nitric oxide (NO), and endogenous
opioids. Progestin receptors often co-localize with estrogen
receptors, and their expression may depend on the estrogen
receptors; they appear to exert synergistic, antagonistic, or
neutral action, depending on the area and the function evalu-
ated [31].
In addition to their central action, sex hormones exert rapid
modulation of vascular tone, without altering gene expression,
through nongenomic mechanisms [32]. In general, female sex
hormones exert a protective action on the cardiovascular sys-
tem through the inhibition of vascular tone, as demonstrated in
different body districts and animal species [33–35]. This ac-
tion is documented for both estrogens and progesterone [36].
17β estradiol induces vasodilatation through genomic and
nongenomic mechanisms: (1) the production of vasodilating
substances such as NO, cyclic guanosine monophosphate, cy-
clic adenosine monophosphate, and prostacyclins; (2) alter-
ation of the expression of their receptors; and (3) alteration
of ion channel activity (calcium and potassium in particular)
[33]. Although endothelial factors may be involved in steroid-
induced vasodilatation [37], it does not appear to play a pre-
ponderant role since vasodilatation occurs also in vessels
without endothelium and with NO inhibitor [36, 38, 39].
Summarizing, the vasodilating action of female sex hormones
involves multiple cellular mechanisms, depending on type of
hormone and type of tissue on which it acts [31].
Female sex hormones modulate the action of many other
hormones and vasoactive neuromediators implicated in the
onset of migraine. The effects of sex hormones depend on
various different factors and can be specific for a certain re-
gion or neuron. Estrogens and progesterone can stimulate
gene expression in one region but inhibit it in another; they
can exert differential actions on the same tissue substrate de-
pending on the hormonal milieu present at a certain moment;
different hormone levels can modulate opposite effects; the
effect on a system can depend on the hormonal stimulation
of other regions connected to it; the action of multiple hor-
mones contemporaneously can differ from the effect of each
single hormone; there may be differences depending on
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whether exposure is acute or chronic; the effect can be ago-
nistic or antagonistic depending on the type of receptor stim-
ulated in the same neurotransmitter [30].
The predominant action of estrogens is to facilitate serotonin-
ergic and glutamatergic tone and to inhibit GABAergic and
noradenergic tone, whereas progesterone stimulates
GABAergic neurons and modulates the effects of estrogens.
Both hormones regulate the pain network and endothelial vascu-
lature [30].
Estrogen administration causes neuronal hyperresponsiveness
of the trigeminal nucleus caudalis (TNC), and progesterone
causes hyporesponsiveness [40, 41]. During the preovulatory
(late follicular) phase (high estrogen, low progesterone levels),
glutamatergic and serotoninergic tone is elevated and sympathet-
ic hypofunction is present, whereas the opposite occurs during
the mid-luteal phase (low estrogen, high progesterone levels).
During the early follicular and late luteal phase (low hormone
levels), sympathetic tone is elevated but GABAergic and seroto-
ninergic tone is low. The rise in estrogen levels during the central
phase of the cycle increases TNC transmission and sets the stage
for periovulatory migraine; however, inhibition by an elevated
serotoninergic level could underlie the lower frequency of
periovulatory compared with menstrual migraine. During the
luteal phase, the increase in progesterone reduces TNC neuro-
transmission. During the late luteal phase and early follicular
phase, the TNC structure changes: the structural changes induced
by estrogens in the TNC are not immediately abolished by the
reduction and could lead to hyperactivation consequent to the
low inhibitory tone due to the decrease in progesterone. This is
a plausible explanation for the greater frequency of migraine
during menses [30].
Calcitonin gene–related peptide (CGRP) Estrogens and proges-
terone can raise CGRP production and modulate its role in pain
transmission [31, 42]. Estrogen therapy was found to increase the
release of CGRP at perivascular sensory nerve endings, resulting in
the vasodilatation of dural arteries in the rat [43]. In vivo studies in
ovariectomized rats showed that treatment with estrogens, proges-
terone, or both increases CGRP and its mRNA in the dorsal root
ganglion [44]. Increased CGRP in the dorsolateral periaqueductal
gray (PAG) was found in ovariectomized mice [45].
Blood CGRP concentration is decreased in postmenopausal
women [46] and increased in pregnant women [47] and those
using contraceptives [48] or hormone replacement therapy [46].
Levels are higher in women than in men [48]. Although elevat-
ed CGRP levels seem to be correlated with migraine, the in-
crease during pregnancy is probably due to vasodilatation and
vascular adaptation; nonetheless, a distinction should be made
between intracerebral and systemic levels [42]. Female sex ste-
roids modulate CGRP levels and mRNA of the receptor and
binding sites. Progesterone exerts an opposite action on the
effects of estrogens and modulates receptor expression opposite
that of estrogens [49].
Experimental models have investigated sex-related differ-
ence in the hormone-induced release of CGRP between
healthy subjects and migraineurs. In healthy men, cutaneous
vessel reactivity was noted to be similar to that of migraineurs,
whereas differences in reactivity were correlated with hor-
monal fluctuations in women, particularly during the
perimenstrual phase. In women migraineurs, reactivity was
more pronounced probably due to the increased release of
CGRP [50]. Studies on the effect of the menstrual cycle on
trigeminal-vascular system reactivity were carried out in
healthy, postmenopausal women and in migraineurs. Greater
reactivity was observed during the menstruation in fertile
women [51], not present in the absence of sex hormones dur-
ing menopause [52]; however, no reactivity of the cutaneous
vessels was noted in the migraineurs during menses [53]. In
another experimental model investigating the effect of sex
hormones, CGRP levels in blood mononuclear cells were
measured in women with pure menstrual migraine. In vitro
treatment with pharmacological doses of 17β estradiol was
observed to increase mRNA levels in the healthy subjects
and the migraineurs, whereas CGRP and mRNA levels were
decreased after administration of physiological doses only in
the migraineurs [52].
Noradrenalin and α receptors Estrogens and progesterone can
stimulate the release of noradrenalin in the hypothalamus,
leading to increased excitability of the ventromedial area
[53]. The rate-limiting step for production of noradrenalin is
tyrosine hydroxylase, whose synthesis is upregulated by es-
trogens [30]. Female mice appear to have a lower pain thresh-
old than male mice and to be less responsive to analgesia
mediated by α receptor agonists [54]. Estrogens appear to
modulate the antinociceptive effect of these receptors: (1)
downregulate α2A receptors in the cortex in ovariectomized
mice [54]; (2) uncouple α2A receptors from protein G [55];
and (3) attenuate the antinociceptive effect in the spine [56].
Plasma adrenalin levels were noted to be higher in female than
in male rats and observed to decrease after ovariectomy [57].
However, estrogens and progesterone reduce sympathetic
tone, consistent with observations in migraineurs and the de-
crease in plasma noradrenalin during menses in migraineurs
compared with controls [58].
In addition to the effects on neurons, sex hormones modu-
late vasoconstriction mediated byα2 receptor agonists, induc-
ing a dichotomic effect depending on the vascular district
involved [31]. Studies have shown that infusion of estrogens
after ovariectomy reduces α2 receptor-mediated vasoconstric-
tion [59]. Increased α2 receptor function may be partly re-
sponsible for elevated blood pressure during postmenopause
[60]. Other data showed a vasoconstrictive effect of estrogen
replacement therapy in ovariectomized mice mediated by α2
receptors, which could be masked by an endothelial influence,
particularly by NO [61].
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Vascular sensitivity to noradrenalin is regulated in opposite
directions by estrogens and progesterone. Female sex hor-
mones can act on noradrenergic receptors, such as releasing
noradrenalin in diverse brain areas. The subsequent increase
in cortical excitability, inhibition of antinociceptive tone, and
modulation of vascular tone are predisposing factors for mi-
graine in women [31].
Serotonin Female sex hormones can modulate the synthesis at
both central and vascular levels. Neurophysiological studies
on primates have demonstrated a link between estrogen and
serotonin mediated by the ERβ receptor [31].
In their study, Nappi et al. used meta-chlorophenylpiperazine
(m-CCP), a 5-HT receptor agonist, to evaluate the involvement
of 5-HT receptor in the occurrence of status migrainosus trig-
gered by discontinuation of combined oral contraceptives
(COCs). They demonstrated that status migrainosus is associated
with impaired neuroendocrine response to 5-HT challenge com-
pared with healthy controls and transdermal estrogen delivered
during the COCs interval improved migraine symptoms and re-
stored 5-HT response [62]. Also, the firing rate of serotoninergic
neurons in the nucleus of the dorsal raphe is higher in male than
female rats [63]. Estrogens stimulate tryptophan hydrolase, the
rate-limiting enzyme in the synthesis of serotonin; this effect does
not seem to be modified by the addition of progesterone [64].
The serotonin reuptake transporter (SERT) is also modulated by
estrogens, the effect of which depends on the duration of hor-
mone therapy. The degradation enzymes MAO-A and MAO-B
are inhibited by estrogens and progesterone [30]. In vitro studies
on the vasoconstrictive action of serotonin have shown a reduc-
tion after exposure to estrogens in diverse vascular districts
through a direct effect on muscle cells but not on the endotheli-
um. Progesterone appears to mediate similar effects alone and in
combination with estrogens [31].
Ion balanceMagnesium and calcium levels are influenced by
sex steroids and vary across the menstrual cycle through ge-
nomic and nongenomic mechanisms. Thus, an increased neu-
ron excitability is caused by an inverse correlation between
estrogen and progesterone and cytoplasmic Mg levels.
Calcium levels increase with increasing estrogen levels.
Calcium and potassium ion channels are coupled with estro-
gen receptors through protein G, which are activated by sex
hormones. It remains to be established whether these modu-
lations are relevant in migraine pathophysiology [31].
Nitric oxide (NO) Estrogens can directly influence vascular
tone by increasing the secretion of NO and its synthesis by
stimulating NO synthetasis in the endothelium [65]. NO and
platelet L-arginine pathways are active in women with men-
strual migraine, particularly during the luteal phase, compared
with women not affected by menstrual migraine and healthy
women [66]. Studies in rats showed that estrogens reduce
arterial tone via a NO-dependent mechanism. The interaction
between sex hormones and nuclear or cytosolic receptors trig-
gers genomic effects that can lead to endothelial cell growth
and inhibit the growth of smooth muscle cells. Nongenomic
effects can also occur, such as stimulation of NO or prostacy-
clin synthesis [31]. In postmenopausal women, vascular func-
tion can be improved with estrogen valerate, which increases
NO levels, whereas combination with medroxyprogesterone
acetate reduces the amount of increase [67].
GABA Activation of GABAergic receptors induces
neuroinhibition, which is influenced by female hormones.
The GABAA receptor opening time is lengthened by stimula-
tion by allopregnanolone, leading to hyperpolarization [68].
Differently, estrogens uncouple the receptor and the G
protein-coupled inward rectifier K+ (GIRK) channels, which
reduces receptor function and increases depolarization [69].
Besides their central action, sex steroids act on GABAergic
receptors in vascular smooth muscle. GABA is one of the
weakest vasodilating substances. However, there is other ev-
idence for estrogen action that estrogens promote GABA syn-
thesis and its release and synapse formation [31].
Glutamate Estrogens and progesterone differ in the effects on
glutamate receptors depending on the brain area where they
act. Acute estrogen exposure increases the firing rate of
Purkinje cells after the application of glutamate [30].
Estrogens promote glutamatergic transmission (N-methyl-d-
aspartate [NMDA] and kainate) in the hippocampus [70], but
the same effects are not observed in other brain areas [70]. In
contrast, progesterone inhibits NMDA receptors in the frontal
cortex [70]. Glutamate receptors appear to be involved in the
peripheral release of CGRP [31].
Endogenous opioids Sex-related differences in morphine-
induced analgesia have been documented in numerous animal
species, including humans [71]. Antinociceptive activation is
greater in men than in women. During pregnancy, enkephalin
and dinorphine levels are increased, as are levels of estrogens and
progesterone [72]. Estrogens and progesterone increase the ex-
pression of mRNA of pro-opiomelanocortin. Their effects differ
depending on the type of receptor and brain area [31].
Brain structure and function
Imaging studies have shown considerable sex-related differ-
ences in the gray and white substance, in numerous functional
networks, and in brain biochemistry. The number of anoma-
lous functioning connections is greater, and the degree of re-
silience against function loss of brain networks is lower in
women [73]. Differences are also related to the menstrual
cycle: the gray matter is thicker during the ovulatory phase.
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In women using hormonal contraceptives, the volume of gray
matter at the frontal cortex, the pre- and postcentral gyro, the
parahippocampus, and the temporal region is greater than in
women with a normal hormonal cycle. Hormonal fluctuations
influence the perception of pain, which may increase suscep-
tibility to migraine attacks at certain points in the menstrual
cycle [74].
Estrogens modulate neuron activity by stimulating the ER
distributed throughout numerous brain areas, many of which
are implicated in the onset of migraine (e.g., the pulvinar, the
accumbens nucleus, and the amygdala). Changes in the vol-
ume or ratio between white and gray matter depending on
cycle phase were observed in the hippocampus, the basal gan-
glia, and the amygdala [74].
Greater thickness of the posterior insula and the precuneus
was noted in women migraineurs compared with men and
healthy controls. Stimulation of heat-induced pain elicits
sex-related differences in response patterns. Based on this ob-
servation, a sex phenotype for migraine has been hypothe-
sized in which sensory and emotional circuitry differs between
men and women [75].
Conclusion
Several factors may modulate female predisposition to mi-
graine throughout genetic and epigenetic mechanisms: hor-
mones, brain structure, genetic polymorphism or mutation,
life events, stress, and neuronal activity. All these are cross-
connected, and they influence each other. This specific sex
phenotype for women should be considered during clinical
management and experimental studies.
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